Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration
- 26 Downloads
The serum concentrations of α1-acid glycoprotein (AAG), albumin (HSA) and non-esterified fatty acids, and the serum binding of tertatolol were measured in four groups of individuals: healthy control subjects (n=24), and patients with inflammation (n=28), and hepatic (n=20) and renal (n=27) insufficiency.
Serum binding of tertatolol was increased in patients with inflammation (94.6%), decreased in patients with hepatic insufficiency (88.8%) and it was unchanged in patients with renal insufficiency (92.8%) as compared to controls (92.7%).
Multivariate analysis indicated that the changes were mainly related to concomitant changes in AAG concentration, which could account for 57% of intersubject variability in the bound/free ratio, and to a lesser extent in HSA, which accounted for only 4% of the variability in the binding.
The data show that the free fraction of the basic drug tertatolol in serum is affected by pathological conditions that cause changes in AAG concentration.
Key wordstertatolol alpha1-acid glycoprotein serum binding AAG-drug interaction renal failure hepatic failure inflammatory syndromes
Unable to display preview. Download preview PDF.
- 1.Paillard F, Lanz B, Leviel F, Ardaillou R (1986) Renal hemodynamic effect of tertatolol in essential hypertension. Am J Nephrol 6 [Suppl 2]: 40–44Google Scholar
- 2.Beaufils M, Lanz B, Paillard F, Richet G (1986) Effects of tertatolol in hypertensive patients with chronic renal failure. Am J Nephrol 6 [Suppl 2]: 50–55Google Scholar
- 3.Campbell DB, Chignon JC, Devissaguet JPh (1986) Biodisposition of tertatolol in man: A review. Am J Nephrol [Suppl 2]: 61–68Google Scholar
- 4.Routledge PhA (1986) The plasma protein binding of basic drugs. Br J Clin Pharmacol 22: 499–506Google Scholar
- 5.Ståhle L, Wold S (1986) On the use of some multivariate statistical methods in pharmacological research. J Pharmacol Methods 16: 91–110Google Scholar
- 6.Müller WE (1986) Drug binding to human α1-acid glycoprotein. Focus on a single binding site. In: Tillement JP, Lindenlaub E (eds) Protein binding and drug transport. Schattauer, Stuttgart New YorkGoogle Scholar
- 7.Urien S (1986) Interaction of drugs with human plasma lipoproteins. In: Tillement JP, Lindenlaub E (eds) Protein binding and drug transport. Schattauer, Stuttgart New YorkGoogle Scholar
- 8.Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borgå O, Sjöqvist F (1971) Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 285: 264–267Google Scholar
- 9.Rudman D, Treadwell PE, Vogler WR, Howard CH, Hollins B (1972) An abnormal orosomucoid in the plasma of patients with neoplasic disease. Cancer Res 32: 1951–1959Google Scholar
- 10.Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schöpf J (1985) Interindividual differences in the binding of antide-pressives to plasma proteins: The role of the variants of α1-acid glycoprotein. Eur J Clin Pharmacol 27: 661–666Google Scholar
- 11.Abramson FP, Jenkins J, Ostchega Y (1982) Effects of cancer and its treatment on plasma concentration of α1-acid glycoprotein and propranolol binding. Clin Pharmacol Ther 32: 659–663Google Scholar
- 12.Sager G, Hansteen V, Aakesson I, Jacobsen S (1981) Effect of heparin on serum binding of propranolol in the acute phase of myocardial infarction. Br J Clin Pharmacol 12: 613–620Google Scholar
- 13.Belpaire FM, Braekman RA, Bogaert MG (1984) Binding of oxprenolol and propranolol to serum, albumin and α1-acid glycoprotein in man and other species. Biochem Pharmacol 33: 2065–2069Google Scholar
- 14.Piafsky KM, Borgå O, Odar-Cederlöf I, Johansson C, Sjöqvist F (1978) Increased plasma protein binding of propranolol and chlorpramazine mediated by disease-induced elevations of plasma α1-acid glycoprotein. N Engl J Med 299: 1435–1438Google Scholar
- 15.Baruzzi A, Contin M, Perucca E, Riva R (1986) Altered serum protein binding of carbamazepine in disease states associated with an increased α1-acid glycoprotein concentration. Eur J Clin Pharmacol 31: 85–89Google Scholar
- 16.Routledge PA, Lazar JD, Barchowsky A, Stargel WW, Wagner GS, Shand DG (1985) A free lignocaine index as a guide to unbound drug concentration. Br J Clin Pharmacol 20: 695–698Google Scholar
- 17.Barré J, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, Tillement JP (1987) Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 23: 753–757Google Scholar
- 18.Pedersen LE, Bonde J, Graudal NA, Backer NV, Hansen JES, Kampmann JP (1987) Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Br J Clin Pharmacol 23: 41–46Google Scholar
- 19.Tiula E, Neuvonen PJ (1986) Effect of total drug concentration on the free fraction in uremic sera. Ther Drug Monitor 8: 27–31Google Scholar
- 20.Pearson RM (1977) Pharmacokinetics and response to diazoxide in renal failure. Clin Pharmacol 2: 198–204Google Scholar
- 21.McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand DG (1976) Plasma binding and the affinity of propranolol for a beta-receptor in man. Clin Pharmacol Ther 20: 152–157Google Scholar
- 22.Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT (1986) Binding to serum α1-acid glycoprotein and effect of β-adrenoceptor antagonists in rats with inflammation. Br J Pharmacol 88: 697–705Google Scholar